INTERVIEW: DPx's Jim Mullen delivers the $2.6bn message
This article was originally published in Scrip
Executive Summary
The recent merger of Patheon and DPP makes the company one of the largest outsourcing players in the market. CEO Jim Mullen explains why the company now has to live up to the hype.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.